LLY260109P1050000.US

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 approves 𝐨𝐫𝐚𝐥 𝐖𝐞𝐠𝐨𝐯𝐲 𝟐𝟓 𝐦𝐠.

➤ Approval covers adults with 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 or overweight with comorbidities.

➤ Oral Wegovy becomes Novo Nordisk's 𝐟𝐢𝐟𝐭𝐡 regulatory approval globally.

➤ OASIS 4 trial showed approximately 𝐒𝟕% mean weight loss over 64 weeks.

➤ Placebo group recorded approximately 𝐒𝟑% mean weight loss.

➤ Around 𝐨𝐧𝐞 𝐢𝐧 𝐭𝐡𝐫𝐞𝐞 participants lost 𝐒𝟐𝟎% or more body weight.

➤ EU also approved 𝐖𝐞𝐠𝐨𝐯𝐲 𝟕.𝟐 𝐦𝐠 single-dose injection pen.

➤ Novo Nordisk says the injection delivers approximately 𝐒𝟐𝟏% weight loss.

➤ Company plans additional global launches in 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐡𝐚𝐥𝐟 𝐨𝐟 𝟐𝟎𝟐𝟔.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

𝐌𝐢𝐤𝐞 𝐃𝐨𝐮𝐬𝐭𝐝𝐚𝐫, president and CEO of Novo Nordisk:

"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment."